Abstract

Improving Survival in Acute Myeloid Leukemia: Pick the Best Subjects?

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia.
Shukaib Arslan ... Guido Marcucci
American journal of hematology | VOL. 96
Shukaib Arslan, et. al.Shukaib Arslan ... Guido Marcucci
08 Dec 2020
Indications for allogeneic hematopoietic cell transplantation for acute myeloid leukemia in the genomic era.
Frederick R Appelbaum
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting | VOL. 34
Frederick R AppelbaumFrederick R Appelbaum
01 May 2014
Comparison Of Minimal Residual Disease As Outcome Predictor For AML Patients In First Complete Remission Undergoing Myeloablative Or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
Roland B Walter ... Brenda M Sandmaier
Blood | VOL. 122
Roland B Walter, et. al.Roland B Walter ... Brenda M Sandmaier
15 Nov 2013
A Markov Decision Analysis of Post-Remission Strategies in 2029 Patients with AML in First Remission (CR1): Should We Perform Allogeneic Hematopoietic Cell Transplantation in CR1?.
Saiko Kurosawa ...
Blood | VOL. 114
Saiko Kurosawa, et. al.Saiko Kurosawa ...
20 Nov 2009
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.
Yoon-Koo Kang ... Sung Hoon Noh
Journal of Clinical Oncology | VOL. -
Yoon-Koo Kang, et. al.Yoon-Koo Kang ... Sung Hoon Noh
12 Jul 2024
Individualized Local Recurrence Estimates for Ductal Carcinoma In Situ.
Laura E G Warren ... Jennifer R Bellon
Journal of Clinical Oncology | VOL. -
Laura E G Warren, et. al.Laura E G Warren ... Jennifer R Bellon
11 Jul 2024
Are Oral Selective Estrogen Receptor Degraders Beneficial for Patients With ESR1-Mutated Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer?
Aoba Okeya ... Chikako Shimizu
Journal of Clinical Oncology | VOL. -
Aoba Okeya, et. al.Aoba Okeya ... Chikako Shimizu
11 Jul 2024
Reply to A. Okeya et al.
Miguel Martín ... Joohyuk Sohn
Journal of Clinical Oncology | VOL. -
Miguel Martín, et. al.Miguel Martín ... Joohyuk Sohn
11 Jul 2024
View more papers